EIR 2024-2026

President & CEO, S2 Genomics

Jonathan Schimmel is President and CEO of S2 Genomics, a single cell genomics sample prep automation company, and the managing partner of Macatawa Capital, a biotech tools and molecular diagnostics focused family office. Jonathan is also a member of Life Science Angels, a Palo Alto based angel investment group, a member of Berkley SkyDeck Advisors, and on the advisory board for Tufts University Graduate School of Biomedical Sciences. 

Previously, Jonathan was VP of Global Support and Sales Operations for 10x Genomics. In this role he was a foundational commercial leader, providing executive leadership in many aspects of 10x’s commercial operations. Jonathan was directly responsible for creating the support strategy and global support organization, including global Order Management. Additionally, Jonathan was responsible for creating the initial Asia Pacific distributor strategy and subsequent leadership of the team. 

Prior to 10x Genomics, Jonathan was President of Seegene Technologies, responsible for leading the commercialization of Seegene’s innovative Multiplex PCR technologies in the US market. Earlier, Jonathan held multiple senior level roles with Bio-Rad Laboratories, including Manager of Customer Operations (Order Management, Technical Support and Service), Manager of Group Marketing (Marketing Operations), finally culminating as the Vice-President and General Manager of the Gene Expression Division. In his time at Bio-Rad, Jonathan provided strategic direction for product concept, development and launch, global strategic marketing direction, and direct accountability for the R&D and marketing budgets. The product areas within his division included: PCR, Real Time PCR (hardware and reagents), Digital PCR Marketing and Commercialization in partnership with the acquired team from QuantaLife, DNA Electrophoresis, DNA Transfection, Cell Counting, Imaging, and Cell Sorting. 

Jonathan holds a BS in Biology from Michigan State University and a PhD in Molecular Biology from Tufts University Graduate School of Biomedical Sciences.